These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 615720)

  • 21. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.
    Davison SC; Hyman NM; Dehghan A; Chan K
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1141-5. PubMed ID: 7334410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful desensitization protocol for pyridostigmine in a 12 year old patient with myasthenia gravis.
    Kaplan F; Topal E
    Turk J Pediatr; 2023; 65(2):326-329. PubMed ID: 37114698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and oral bioavailability of pyridostigmine in man.
    Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO
    Eur J Clin Pharmacol; 1980 Nov; 18(5):423-8. PubMed ID: 7439266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial.
    Sieb JP; Köhler W
    Clin Neurol Neurosurg; 2010 Nov; 112(9):781-4. PubMed ID: 20663605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
    Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO; Stålberg E
    J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):929-35. PubMed ID: 6644317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous infusion of pyridostigmine for myasthenic crisis.
    Nicholson J; Grant IS
    Crit Care Med; 1994 May; 22(5):895-6. PubMed ID: 8181302
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of the myasthenic syndrome with Mestinon retard].
    Mittelbach F; Pongratz D
    Munch Med Wochenschr; 1968 May; 110(22):1375-80. PubMed ID: 5755631
    [No Abstract]   [Full Text] [Related]  

  • 28. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
    Schumm F; Gaertner HJ; Wiatr G; Dichgans J
    Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyridostigmine levels in myasthenia gravis.
    Kornfeld P; Mittag T; Genkins G; Papatestas AE; Horowitz SH
    Neurology; 1977 Nov; 27(11):1099. PubMed ID: 563008
    [No Abstract]   [Full Text] [Related]  

  • 30. [Conservative treatment of pseudoparalytic myasthenia gravis].
    Vieth J
    Med Welt; 1971 Sep; 38():1496. PubMed ID: 5097679
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of myasthenia gravis with pyridostigmine.
    Grogan WA
    Arch Neurol; 1987 Oct; 44(10):995-6. PubMed ID: 3632385
    [No Abstract]   [Full Text] [Related]  

  • 32. Continuous infusion of pyridostigmine in the management of myasthenic crisis.
    Saltis LM; Martin BR; Traeger SM; Bonfiglio MF
    Crit Care Med; 1993 Jun; 21(6):938-40. PubMed ID: 8504663
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis.
    Caifeng S; Jingsheng Z; Yi L; Xueshi H; Zhanyou W; Haiou P; Wenjun Q
    J Tradit Chin Med; 2022 Oct; 42(5):810-817. PubMed ID: 36083490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapetic measures in myasthenia gravis].
    Cavaciuti P; Gatti E
    Minerva Anestesiol; 1969 Aug; 35(8):765-79. PubMed ID: 5364124
    [No Abstract]   [Full Text] [Related]  

  • 35. Determination of neostigmine and pyridostigmine in the urine of patients with myasthenia gravis.
    NOWELL PT; SCOTT CA; WILSON A
    Br J Pharmacol Chemother; 1962 Jun; 18(3):617-24. PubMed ID: 14480648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pro-arrhythmia effect of pyridostigmine. Apropos of a case].
    Leenhardt A; Thomas O; Haouala H; Benaïm R; Maison-Blanche P; Cauchemez B; Haguenau M; Coumel P; Slama R
    Arch Mal Coeur Vaiss; 1992 Dec; 85(12):1853-6. PubMed ID: 1306628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of cholinesterase inhibitors.
    Aquilonius SM; Hartvig P
    Clin Pharmacokinet; 1986; 11(3):236-49. PubMed ID: 3524957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long term treatment of myasthenia gravis with azathioprine.
    Fonseca V; Havard CW
    Postgrad Med J; 1990 Feb; 66(772):102-5. PubMed ID: 2112245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prepubertal muscle-specific kinase myasthenia with a long and benign natural course.
    Zouvelou V; Velonakis G
    Muscle Nerve; 2016 Jun; 53(6):989. PubMed ID: 26663151
    [No Abstract]   [Full Text] [Related]  

  • 40. Myasthenia gravis.
    Murray KB
    Kans Med; 1990 Jun; 91(6):181-3. PubMed ID: 2398638
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.